Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2561 to 2570 of 2582 total matches.
Correction: Vancomycin Dosing and Monitoring
The Medical Letter on Drugs and Therapeutics • Apr 20, 2009 (Issue 1310)
Subscriptions (US):
1 year - $98; 2 years - $167;
3 years - $235. $49.00 per year for
students, interns ...
(Med Lett Drugs Ther 2009; 51:25) In the paragraph on dosing, the second-to-last sentence should have said that the new recommendations suggest considering use of an alternative antibiotic when the MIC for the infecting organism is ≥2 mg/L, not >2 mg/L.
Table 3: Some Drug Interactions with DAAs for HCV Infection (online only)
The Medical Letter on Drugs and Therapeutics • Oct 28, 2024 (Issue 1714)
; OATP = organic anion transporting polypeptide.
1. The University of Liverpool maintains ...
View Table 3: Some Drug Interactions with DAAs for HCV Infection
Med Lett Drugs Ther. 2024 Oct 28;66(1714):e175 doi:10.58347/tml.2024.1714f | Show Introduction Hide Introduction
Hemolysis From Ceftriaxone
The Medical Letter on Drugs and Therapeutics • Nov 25, 2002 (Issue 1144)
Web Site: www.medicalletter.org
Subscriptions (U.S.)
1 year-$59; 2 years-$99; 3 years-$142.
$29.50 ...
Immune-mediated hemolysis is a rare adverse effect of second- and third-generation cephalosporins, especially cefotetan (Cefotan) (PA Arndt et al, Transfusion 1999; 39:1239). A recent report serves as a reminder that life-threatening immune-mediated hemolysis rarely can follow administration of ceftriaxone (Rocephin), one of the most commonly used parenteral antibiotics in the US (A Citak et al, J Paediatr Child Health 2002; 38:209).
Ophthalmic Cyclosporine (Restasis) for Dry Eyes
The Medical Letter on Drugs and Therapeutics • May 26, 2003 (Issue 1157)
-632-1733
Web Site: www.medicalletter.org
Subscriptions (U.S.)
1 year-$59; 2 years-$99; 3 years-$142 ...
A cyclosporine 0.05% ophthalmic emulsion (Restasis - Allergan) has been approved by the FDA for use in patients with dry eye disease (keratoconjunctivitis sicca). This review begins with a discussion of the causes of dry eye disease and includes sections on the pharmacology, adverse effects and clinical trial results for ophthalmic cyclosporine. Cost information and recommendations for administering the drug are also presented. The review concludes with an overall assessment of the drug's efficacy, safety and cost.
Atomoxetine (Strattera) Revisited
The Medical Letter on Drugs and Therapeutics • Aug 16, 2004 (Issue 1189)
to disclose any potential conflict of interest.
Subscriptions (U.S.)
1 year-$63; 2 years-$107; 3 years-$151 ...
Atomoxetine (Strattera - Lilly), a nonstimulant drug that is not a controlled substance, was approved by the FDA in early 2003 for the treatment of attention deficit hyperactivity disorder (ADHD). At that time, The Medical Letter concluded that it was unclear whether atomoxetine was as effective as stimulants such as methylphenidate (Concerta, and others) (Medical Letter 2003; 45:11). Since then, the drug has been heavily advertised directly to the public for use in both children and...
In Brief: Atorvastatin for Stroke Prevention
The Medical Letter on Drugs and Therapeutics • Sep 11, 2006 (Issue 1243)
-mail your request to:
permissions@medicalletter.org
Subscriptions (US):
1 year - $89; 2 years - $151 ...
Statins have been shown to reduce the risk of stroke in patients at high risk for cardiovascular disease (Treat Guidel Med Lett 2005; 3:15). A recent issue of The New England Journal of Medicine includes the results of a study sponsored by the manufacturer in which 80 mg of atorvastatin (Lipitor – Pfizer) or placebo was given to 4731 patients without coronary artery disease who had had a stroke or transient ischemic attack (TIA) within one to six months before study entry (The Stroke Prevention by Aggressive Reduction in Cholesterol Levels [SPARCL] Investigators. High-dose atorvastatin after...
Addendum: Why Not Ertapenem for Surgical Prophylaxis?
The Medical Letter on Drugs and Therapeutics • Sep 07, 2009 (Issue 1320)
to:
permissions@medicalletter.org
Subscriptions (US):
1 year - $98; 2 years - $167;
3 years - $235. $49.00 ...
Some readers have asked why the June 2009 issue of Treatment Guidelines (Antimicrobial Prophylaxis for Surgery) did not recommend use of ertapenem (Invanz) for prevention of infection after elective colorectal surgery. Ertapenem is a broad-spectrum carbapenem that has been approved for such use by the FDA. Medical Letter consultants do not recommend use of broad-spectrum drugs such as ertapenem, third-generation cephalosporins such as cefotaxime (Claforan), ceftriaxone (Rocephin), cefoperazone (Cefobid), ceftazidime (Fortaz, and others) or ceftizoxime (Cefizox), or fourth-generation...
Addendum: Cost of Ustekinumab (Stelara)
The Medical Letter on Drugs and Therapeutics • Mar 08, 2010 (Issue 1333)
Subscriptions (US):
1 year - $98; 2 years - $167;
3 years - $235. $49.00 per year for
students, interns ...
In the Medical Letter article on ustekinumab (Stelara) for psoriasis (2010; 52:7), footnote 2 in table 2 should have included a second sentence: $5595.60 is the cost of one 45-mg syringe.
Blue light (ClearLight) for Acne Vulgaris
The Medical Letter on Drugs and Therapeutics • Jun 23, 2003 (Issue 1159)
-235-0500 Fax: 914-632-1733
Web Site: www.medicalletter.org
Subscriptions (U.S.)
1 year-$59; 2 years ...
A high-intensity, narrow-band blue light (ClearLight -Lumenis) approved by the FDA for treatment of moderate inflammatory acne vulgaris has been featured in some stories in fashion magazines. This review describes the etiology and treatment of acne, as well as the mechanism of action, clinical studies, adverse effects, dosage and cost of the drug.
Tdap, DTaP Mix-Ups
The Medical Letter on Drugs and Therapeutics • Jan 15, 2007 (Issue 1252)
to:
permissions@medicalletter.org
Subscriptions (US):
1 year - $89; 2 years - $151;
3 years - $214. $44.50 ...
Medical Letter consultants have brought to our attention some confusion that has accompanied the release of Adacel, a combination of tetanus toxoid, diphtheria toxoid and acellular pertussis antigens (Tdap) recently approved for use as a booster in adolescents and adults 11-64 years old (Med Lett Drugs Ther 2006; 48:5). Another Tdap vaccine, Boostrix, is approved for use in adolescents 10-18 years old. Some adults have inadvertently been immunized with Daptacel or Infanrix (DTaP), which are intended for active immunization of infants and children 6 weeks to 6 years old. Such mix-ups were...